Novartis
The Latest
-
FDA Cautions Doctors On Use Of Hydroxychloroquine To Fight COVID-19
COVID-19, the infection caused by the novel coronavirus, has no approved treatment or vaccine. COVID-19, the infection caused by the novel coronavirus, has no approved treatment or vaccine. -
Novartis Given FDA Green Light To Test 440 Patients Using Malaria Drug
Novartis to donate up to 130 million tablets of hydroxychloroquine to support global clinical trials Novartis to donate up to 130 million tablets of hydroxychloroquine to support global clinical trials -
Novartis, Other Drug Firms Believe Malaria Drug Can Treat Coronavirus
FDA said it is waiting for more clinical testing before authorizing hydroxychloroquine for general use. FDA said it is waiting for more clinical testing before authorizing hydroxychloroquine for general use. -
Drugmakers Investing Billions In Building Internal Gene Therapy Facilities
Since 2018, major drugmakers have invested a combined $2 billion in establishing their own gene therapy manufacturing facilities. Since 2018, major drugmakers have invested a combined $2 billion in establishing their own gene therapy manufacturing facilities. -
Novartis, The Medicines Co To Ink $9.7 Billion Buyout Deal
Buyout deal approved by both the company's board of directors through cash and short-and long-term loan. Buyout deal approved by both the company's board of directors through cash and short-and long-term loan. -
Novartis Seeking Approval For 50 New Drugs In China
Swiss pharmaceutical giant Novartis has submitted 50 new drugs aimed at treating Asia-specific diseases to Chinese regulators for approval. Swiss pharmaceutical giant Novartis has submitted 50 new drugs aimed at treating Asia-specific diseases to Chinese regulators for approval. -
FDA Approves World's Most Expensive Drug Priced At $2.1 Million
Novartis' Zolgensma drug is a one-time gene therapy treatment for people suffering from spinal muscular atrophy. Novartis' Zolgensma drug is a one-time gene therapy treatment for people suffering from spinal muscular atrophy. -
Novartis Unveils Ultra-Expensive US$2 Million Wonder Drug
Novartis' latest gene-therapy drug Zolgensma, currently awaiting FDA approval, will reportedly cost US$2 million per treatment. cf Novartis' latest gene-therapy drug Zolgensma, currently awaiting FDA approval, will reportedly cost US$2 million per treatment. cf